| Literature DB >> 23459571 |
Tomas Olsson1, Anat Achiron, Lars Alfredsson, Thomas Berger, David Brassat, Andrew Chan, Giancarlo Comi, Mefkure Eraksoy, Harald Hegen, Jan Hillert, Poul Erik Hyldgaard Jensen, Lucia Moiola, Kjell-Morten Myhr, Annette Oturai, Sven Schippling, Aksel Siva, Per Soelberg Sorensen, Anne-Kathrin Trampe, Thomas Weber, James Potts, Tatiana Plavina, Dominic Paes, Meena Subramanyam, Heinz Wiendl, Hussein Dib, Deniz Uren, Bernhard Hemmer, Dorothea Buck.
Abstract
JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients < 30 years of age to 66.5% in patients ≥ 60 years of age; p < 0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p < 0.0001) and was not affected by prior immunosuppressant or natalizumab use.Entities:
Keywords: JC virus; Multiple sclerosis; STRATIFY-JCV; anti-JCV antibodies; antibody prevalence; brain infection; epidemiology; immunosuppressant therapy; infection risk; international study; natalizumab
Mesh：
Substances：
Year: 2013 PMID： 23459571 DOI： 10.1177/1352458513477925
Source DB: PubMed Journal: Mult Scler ISSN： 1352-4585 Impact factor: 6.312